Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 11 August 2014 | By Alexander Gaffney, RAC,
South Korean biopharmaceutical manufacturer Celltrion has announced that it has filed an application for approval with the US Food and Drug Administration (FDA) for Remsima, its biosimilar version of Jannsen's Remicade (infliximab).
The company's biosimilar filing is the second-ever filing of a drug through FDA's new 351(k) biosimilar pathway, and reportedly the first-ever monoclonal antibody (mAb) to seek approval through the pathway.
The first biosimilar filing for approval was submitted on 24 July 2014 by Sandoz, which is seeking approval for Zarzio, a biosimilar version of Neupogen (filgrastim).
Like Sandoz's Zarzio, Celltrion's Remsima will have to overcome many difficult regulatory challenges prior to obtaining FDA's stamp of approval, including how "similar" FDA will find Remsima to Remicade.
FDA has explained that it plans to hold biosimilar products to a four-part standard for biosimilarity:
But aside from explaining that the standard would be used by regulators, FDA has so far offered little in the way of details about how drugs might find themselves in each of the four categories.
Zarzio and Remsima are also likely to be the first drugs to be subject to FDA's unreleased biosimilar naming guidance, which will determine what the drugs' nonproprietary names should be, and fights over whether the drugs are similar enough to be interchangeable with the reference biologic on which their approval is based.
Like Sandoz, Celltrion isn't seeking approval for an untested product. Remsima, like Zarzio, has obtained approval in several dozen countries and regions, including in Canada, Japan and the EU. Celltrion said the product is the only biosimilar monoclonal antibody to be approved simultaneously in all three regions.
Celltrion said it anticipates receiving FDA approval for Remsima within 12 months, though it cautioned that a patent on the drug owned by Janssen expires in 2018. It is challenging all remaining patents in court—a process which could slow approval.
Celltrion Announcement
Tags: Biosimilar, Biosimilarity, Remsima, Celltrion, 351(k), Monoclonal Antibody
Regulatory Focus newsletters
All the biggest regulatory news and happenings.